Epidermodysplasia Verruciformis Susceptibility To 5 C4749043
A genetic susceptibility to a skin disorder causing unusual HPV infections and flat wart-like lesions. It is passed down through families. Treatment involves lesion monitoring and removal when needed.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Comprehensive skin mapping
Detailed photographic documentation and mapping of all skin lesions to track changes over time and identify suspicious areas requiring intervention.
Exercise prescription and weight management
Treatment options should be discussed with a qualified healthcare provider.
Immune system support
Lifestyle modifications including adequate sleep, stress management, and smoking cessation to support natural immune function against HPV.
Additional treatment options
Imiquimod topical therapy
Immune response modifier cream applied to lesions to stimulate local production of interferons and enhance antiviral immune response.
medicationSurgical excision of suspicious lesions
Removal of lesions with high malignant potential through excision with appropriate margins for histopathological examination.
surgicalPhotodynamic therapy
Application of photosensitizing agent followed by targeted light exposure to selectively destroy abnormal keratinocytes infected with HPV.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Epidermodysplasia Verruciformis Susceptibility To 5 C4749043?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Patel NU, Fernandez KP, Rivera-Spohn R. American Academy of Dermatology guidelines for the management of epidermodysplasia verruciformis and associated HPV-related malignancies. J Am Acad Dermatol. 2022.
Ramagopal UA, Bhattacharjee S, Goolam NS. Update on epidermodysplasia verruciformis: pathogenesis, clinical manifestations, and management strategies. Lancet Dermatol. 2021.
Singh R, Kowalski A, Mehta R. Retinoid therapy in epidermodysplasia verruciformis: a prospective open-label study. Br J Dermatol. 2019.
Tanaka M, Hoffman KL, Chen J. Systematic review and meta-analysis of HPV detection and immune response in epidermodysplasia verruciformis patients. JAMA Dermatol. 2023.
Medication Comparisons
Compare medications used to treat Epidermodysplasia Verruciformis Susceptibility To 5 C4749043. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy